Intuitive Surgical, Inc. (NASDAQ:ISRG) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have received an average recommendation of “Moderate Buy” from the eighteen research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fifteen have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $583.83.

ISRG has been the subject of several research reports. Piper Sandler reaffirmed an “overweight” rating and set a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a research note on Friday. Wells Fargo & Company increased their price target on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a research report on Friday. Truist Financial raised their price objective on shares of Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research note on Friday. Citigroup upped their target price on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research note on Friday. Finally, Stifel Nicolaus boosted their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, December 5th.

Insider Activity at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $506.52, for a total transaction of $95,225.76. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,788,899.12. This trade represents a 3.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jamie Samath sold 108 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at $4,746,819.42. This represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,453 shares of company stock worth $22,059,506. 0.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors and hedge funds have recently made changes to their positions in the business. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth about $26,000. Godsey & Gibb Inc. raised its stake in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. bought a new position in Intuitive Surgical during the 3rd quarter worth approximately $33,000. Decker Retirement Planning Inc. acquired a new position in shares of Intuitive Surgical in the 4th quarter worth approximately $36,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of Intuitive Surgical in the 3rd quarter valued at approximately $38,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

ISRG opened at $584.05 on Monday. The stock’s 50 day simple moving average is $547.16 and its 200 day simple moving average is $504.78. The stock has a market cap of $208.03 billion, a P/E ratio of 93.90, a P/E/G ratio of 5.19 and a beta of 1.39. Intuitive Surgical has a 1-year low of $364.17 and a 1-year high of $616.00.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.